** Shares of Immuron rise as much as 16.3% to A$0.10, set for their strongest session since April 10, 2024, if gains hold
** The biopharmaceutical co hits highest level since early October
** Co submits clinical study report for its recently completed Phase 2 study of Travelan to the U.S. FDA
** Travelan is one of co's flagship products aimed at reducing the likelihood of contracting traveler's diarrhoea
** Study implies that Travelan aids the reduction of pathological diarrhoea-causing bacteria over time
** About 1.8 mln shares change hands, 28.6 times compared with the 30-day average volume of 63,415 shares
** Stock rose 2.6% in 2024
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@ThomsonReuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.